Jaguar Gene Therapy utilizes an AAV gene therapy platform to develop safe and effective treatments for patients with severe genetic diseases, addressing the lack of viable options for these conditions. By partnering with Advanced Medicine Partners, the company ensures a scalable manufacturing process that prioritizes product purity and patient safety.
Funding
$180M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JTSVFounders
Product
Problem
Patients with severe genetic diseases often lack effective treatments that address the underlying genetic cause of their condition. Many are told that there are no viable options to alter the course of their disease.
Solution
Jaguar Gene Therapy develops adeno-associated virus (AAV) gene therapies for severe genetic diseases. The company leverages a manufacturing process designed to minimize development risk and deliver safe, effective therapies. Jaguar Gene Therapy is also evaluating next-generation technologies, including novel capsids and delivery methods, to improve product purity and efficacy.
Target Audience
The primary target audience is patients suffering from severe genetic diseases and their families, as well as healthcare providers seeking effective treatments for these conditions.
Features
- AAV gene therapy platform for targeted gene delivery
- Focus on severe genetic diseases with unmet medical needs
- Scalable manufacturing process with Advanced Medicine Partners
- Evaluation of next-generation technologies, including novel capsids and delivery methods